New Start/Stop Automation Available for Mission-Critical SAP® Applications Running on Virtustream Enterprise Cloud
9.9.2020 14:00:00 EEST | Business Wire | Press release
Virtustream, an enterprise-class cloud company and Dell Technologies business, announced the availability of new start/stop automation for SAP® software landscapes and systems to help enterprises optimize their costs and controls through new self-service tools and step-by-step status updates. The functionality is now available in the Virtustream Enterprise Cloud via the xStream portal.
“Virtustream consistently drives new innovation into its Virtustream Enterprise Cloud platform to meet our demanding requirements and evolving mission-critical needs in the cloud,” says Ettore Tenaglia, Head of Service Operations, Almaviva. “The new automated features and tools help to improve our oversight, management and controls of our SAP environments, allowing us to optimize our processes to save valuable time and costs which can go back into our business.”
Address Compute Costs with Workload Automation
Virtustream’s new automated services reduce the amount of time and manual effort required from an organization’s internal IT team to perform start/stop commands on SAP landscapes and systems. The new tools and features include:
- Strategic Scheduling: Start/stop operations can be scheduled through the Virtustream xStream portal in 30-minute windows on a one-time, on-demand, or recurring basis (daily, weekly or free-form). Additionally, users can set an expiration date for the agentless operation. Creating customized schedules to power virtual machines on or off helps to reduce compute costs. Additionally, automatically shutting down applications when they aren’t being used, such as during weekends and maintenance periods, can further optimize costs.
- Defined Prioritization: Customers can assign each SAP system a set priority, allowing them to stagger the start/stop of their system so they proceed in a defined order, helping to ensure applications run efficiently and correctly.
- Improved Access Control: Only approved administrators or users can access and use the start/stop automation, as dictated by the enterprise’s permission controls within their xStream tenant.
- New Status Updates, Customized Notifications and Action Logs: A new status bar indicates the step-by-step process of each action as it progresses through the SAP system or landscape. Additionally, customized email notifications can be sent to each administrator based on actions (all actions or only scheduled) or by result (all results or failed only). An action log is generated for each system that shows all actions run on a specific SAP system or landscape including who initiated the action, when it was completed, and what actions were taken.
“Automation is key to streamlining IT operations and increasing cloud agility while freeing internal resources to focus on higher-priority projects or initiatives,” says Mike Zolla, Vice President of Cloud Platform Engineering and Delivery, Virtustream. “By extending automation deeper into our mission-critical Virtustream Enterprise Cloud platform, we are helping our enterprise customers increase the economic and business benefits of their SAP applications.”
Backed by Virtustream’s extensive experience migrating, optimizing and managing SAP workloads in the cloud, Virtustream’s new start/stop automation capability is available across all xStream-supported databases. Virtustream’s xStream Management Platform provides a powerful cloud management platform with a single interface across complex, distributed IT environments. xStream delivers economic and business benefits for a broad range of mission-critical enterprise applications in the cloud.
About Virtustream
Virtustream LLC, a Dell Technologies business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies, Virtustream’s xStreamCare professional and managed services, and the xStream® Management Platform and Infrastructure-as-a-Service (IaaS) meet the security, compliance, performance, efficiency, and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005255/en/
Contact information
For press inquiries:
See the Virtustream newsroom
Frank E. Smith
Head of Global Communications, Virtustream
Frank.E.Smith@Virtustream.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom